A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer (NCT04036682)

🧪 Interventions in This Study

• CLN-081 (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (64 Sites)

Showing the first 25 of 64 sites.

• Pacific Cancer Medical Center, Inc — Anaheim, California
• City of Hope Comprehensive Cancer Center — Duarte, California
• City of Hope at Irvine Lennar — Irvine, California
• Pacific Shores Medical Group — Long Beach, California
• AdventHealth — Orlando, Florida
• Massachusetts General Hospital — Boston, Massachusetts
• University of Michigan Health System - University Hospital — Ann Arbor, Michigan
• Summit Medical Group PA — Florham Park, New Jersey
• Perlmutter Cancer Center at NYU Langone Hospital - Long Island — Mineola, New York
• New York University Langone Health — New York, New York
• Columbia University Irving Medical Center — New York, New York
• Memorial Sloan Kettering Cancer Center — New York, New York
• Gabrail Cancer Center Research — Canton, Ohio
• Providence Cancer Center — Portland, Oregon
• Providence Oncology & Hematology Care Clinic-Westside — Portland, Oregon
• UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
• Medical University of South Carolina — Charleston, South Carolina
• Virginia Cancer Specialists — Fairfax, Virginia
• Hong Kong University - Queen Mary Hospital — Hong Kong,
• Azienda Ospedaliero Universitaria Careggi — Careggi,
• Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I — Marche,
• Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS — Meldola,
• IRCCS-Istituto Europeo di Oncologia — Milan,
• Azienda Ospedaliero Universitaria Modena — Modena,
• San Gerardo Hospital — Monza,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Non Small Cell Lung Cancer

• The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to Surveillance — Boston, Massachusetts
• A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer — Middletown, New Jersey
• Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC — Beverly Hills, California
• Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer — Columbus, Georgia
• Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease — Edmonton, Alberta
• A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer — Springdale, Arkansas

Explore by condition: All Non Small Cell Lung Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.